ATE439354T1 - Pharmazeutische salze von reboxetin - Google Patents

Pharmazeutische salze von reboxetin

Info

Publication number
ATE439354T1
ATE439354T1 AT03725195T AT03725195T ATE439354T1 AT E439354 T1 ATE439354 T1 AT E439354T1 AT 03725195 T AT03725195 T AT 03725195T AT 03725195 T AT03725195 T AT 03725195T AT E439354 T1 ATE439354 T1 AT E439354T1
Authority
AT
Austria
Prior art keywords
reboxetine
pharmaceutical salts
pharmaceutical
salts
Prior art date
Application number
AT03725195T
Other languages
English (en)
Inventor
Massimo Zampieri
Annalisa Airoldi
Alessandro Martini
Original Assignee
Pfizer Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29724495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE439354(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Italia Srl filed Critical Pfizer Italia Srl
Application granted granted Critical
Publication of ATE439354T1 publication Critical patent/ATE439354T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03725195T 2002-06-17 2003-06-04 Pharmazeutische salze von reboxetin ATE439354T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02077366 2002-06-17
PCT/EP2003/005261 WO2003106441A1 (en) 2002-06-17 2003-06-04 Pharmaceutical salts of reboxetine

Publications (1)

Publication Number Publication Date
ATE439354T1 true ATE439354T1 (de) 2009-08-15

Family

ID=29724495

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03725195T ATE439354T1 (de) 2002-06-17 2003-06-04 Pharmazeutische salze von reboxetin

Country Status (24)

Country Link
US (2) US20070010517A1 (de)
EP (1) EP1515959B1 (de)
JP (1) JP4563172B2 (de)
KR (1) KR100779786B1 (de)
CN (2) CN1662511B (de)
AR (1) AR040222A1 (de)
AT (1) ATE439354T1 (de)
AU (1) AU2003227755B2 (de)
BR (1) BR0311878A (de)
CA (1) CA2489763C (de)
DE (1) DE60328787D1 (de)
DK (1) DK1515959T3 (de)
ES (1) ES2328472T3 (de)
HK (1) HK1077572A1 (de)
MX (1) MXPA04011916A (de)
MY (1) MY131231A (de)
NO (1) NO329346B1 (de)
NZ (1) NZ537023A (de)
PE (1) PE20040565A1 (de)
PL (1) PL375211A1 (de)
RU (1) RU2286341C2 (de)
TW (1) TWI267510B (de)
WO (1) WO2003106441A1 (de)
ZA (1) ZA200409624B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319793D0 (en) 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
WO2005082869A1 (en) * 2004-02-20 2005-09-09 Pharmacia & Upjohn Company Llc Method for the preparation of aryl ethers
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20190185438A1 (en) * 2016-12-06 2019-06-20 Tonix Pharmaceuticals Holding Corp. Salts and polymorphs of esreboxetine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2167407B (en) * 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
AU9214498A (en) * 1997-09-23 1999-04-12 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
IT1305322B1 (it) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
SK286669B6 (sk) * 1999-07-01 2009-03-05 Pharmacia & Upjohn Company Použitie opticky čistého (S,S)-reboxetínu alebo jeho farmaceuticky prijateľnej soli na výrobu lieku na liečenie alebo prevenciu periférnej neuropatie

Also Published As

Publication number Publication date
MY131231A (en) 2007-07-31
TW200403230A (en) 2004-03-01
NZ537023A (en) 2006-09-29
TWI267510B (en) 2006-12-01
CN1662511A (zh) 2005-08-31
WO2003106441A1 (en) 2003-12-24
PL375211A1 (en) 2005-11-28
CN101298440A (zh) 2008-11-05
JP4563172B2 (ja) 2010-10-13
EP1515959B1 (de) 2009-08-12
US20090291953A1 (en) 2009-11-26
DE60328787D1 (de) 2009-09-24
BR0311878A (pt) 2005-04-05
CN1662511B (zh) 2010-06-09
KR100779786B1 (ko) 2007-11-28
RU2005100846A (ru) 2005-06-10
NO329346B1 (no) 2010-10-04
CA2489763C (en) 2007-12-18
HK1077572A1 (en) 2006-02-17
EP1515959A1 (de) 2005-03-23
AR040222A1 (es) 2005-03-16
AU2003227755A1 (en) 2003-12-31
MXPA04011916A (es) 2005-03-31
KR20050019137A (ko) 2005-02-28
US20070010517A1 (en) 2007-01-11
JP2005533791A (ja) 2005-11-10
AU2003227755B2 (en) 2009-01-15
PE20040565A1 (es) 2004-09-02
CA2489763A1 (en) 2003-12-24
NO20050183L (no) 2005-01-12
ZA200409624B (en) 2006-05-31
ES2328472T3 (es) 2009-11-13
RU2286341C2 (ru) 2006-10-27
DK1515959T3 (da) 2009-11-02

Similar Documents

Publication Publication Date Title
NO2023030I1 (no) Apixaban and pharmaceutical acceptable salts thereof
DE50212273D1 (de) Pharmazeutische salze von 1-phenyl-3-dimethylamino-propan-verbindungen
DE60333294D1 (de) Kontrollierte verabreichung von arzneien
DE60201859D1 (de) Pharmazeutische Verwendung von N-Carbamoylazol-Derivate
DE60324099D1 (de) Arzneistoffhaltiger tampon
ATE282428T1 (de) Pharmazeutische dosierungsform von amorphem nilfenavir mesylat
CY2017048I2 (el) Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
CY2018005I1 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
IS7946A (is) Lyf
ATE309789T1 (de) Darreichungsform von ibuprofen-natrium
DE60213592D1 (de) Flüssige pharmazeutische zusammensetzung
IS7571A (is) Ný lífeðlisfræðilega virk efni
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE60336999D1 (de) Melatonin enthaltende pharmazeutische formulierung
ATE443512T1 (de) Pharmazeutische zusammensetzung von piperazinderivaten
NO20050183L (no) Farmasoytiske salter av reboxetin
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
ATE349213T1 (de) Nasale pharmazeutische zusammensetzung von piribedil
DE10107261B4 (de) Pharmazeutische Zusammensetzung
PT1467737E (pt) Composicao farmaceutica orodispersivel de piribedil
ATA14072002A (de) Pharmazeutische zubereitung von diclofenac-natrium
SE0200022D0 (sv) Novel mode of drug administration
SE0200449D0 (sv) Pharmaceutical formulation
SE0201660D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties